Phase III Clinical Trial

Cambridge, UK — September 4, 2026 AstraZeneca announced that ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor has received...

Hong Kong, September 3, 2026 Akeso, Inc. has announced that a prespecified interim analysis of overall survival (OS) in...

Hong Kong, China, August 30, 2026 Ascletis Pharma Inc. announced that the first participant has been dosed in its...

August 25, 2026 | Miami, Florida, USA Summit Therapeutics Inc. has announced the publication of primary analysis results from...

BEIJING, August 18, 2026 InnoCare Pharma announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products...

SHANGHAI, China, August 12, 2026 Laekna announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug...

Hong Kong – August 3, 2026 Ascletis Pharma Inc. has initiated a global Phase III clinical development program for...

COPENHAGEN, Denmark, June 18, 2026 Mabwell, an innovation-driven biopharmaceutical company with a fully integrated industry chain, has unveiled encouraging...

Dateline – New Orleans, USA, Feb. 5, 2026 — Bayer announced that its investigational oral Factor XIa inhibitor asundexian...

Nashville, Tenn., January 13, 2026 — Revance and Teoxane announced that the U.S. Food and Drug Administration has approved...